In many solid tumors, including NSCLC, the assessment of PD-L1 expression on the surface of tumor cells is recognized to be a highly significant predictive factor for the effectiveness of immunotherapy with PD-1 inhibitors. This evidence concerns the gene CD274 and neoplasm.